Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, 250012, China.
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan, 250012, China.
Eur J Med Chem. 2021 Nov 15;224:113723. doi: 10.1016/j.ejmech.2021.113723. Epub 2021 Jul 26.
The death caused by pathogenic bacteria has always been a severe threat to mankind. The prevalence of drug resistance among bacteria underscores an urgent goal for new antibacterial agents with novel mode of action. Here we first designed and synthesized a class of benzothiazolyl-5-methylphenanthridium derivatives and evaluated their antibacterial activity. On this basis, we further designed and synthesized another class of novel indolyl-5-methylphenanthridium derivatives by optimizing the benzothiazolyl-5-methylphenanthridium core and evaluated their antibacterial activity targeting the bacterial cell division protein FtsZ. The results showed that the indolyl-5-methylphenanthridium derivatives had greatly improved activity against various drug-resistant bacterial strains including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus (VRE). Among them, compound C5 displayed excellent antibacterial activity against susceptible (MIC = 1 μg/mL), methicillin-resistant and clinical isolated S. aureus (MIC = 2 μg/mL). With low hemolytic activity towards mice red blood cells, C5 exhibited good antibacterial effect in vivo in preliminary pharmacodynamic assay. More importantly, C5 was difficult to induce bacterial resistance. Further mechanism studies proved that C5 could inhibit bacterial cell division by promoting FtsZ polymerization, leading to disorderly polymerization and disordered knots. Therefore, our findings suggest that this class of novel indolyl-5-methylphenanthridium derivatives are promising for future antibacterial agents.
致病细菌导致的死亡一直以来都是对人类的严重威胁。细菌耐药性的流行凸显了开发具有新型作用机制的新型抗菌药物的紧迫目标。在这里,我们首次设计并合成了一类苯并噻唑基-5-甲基菲啶衍生物,并评估了它们的抗菌活性。在此基础上,我们通过优化苯并噻唑基-5-甲基菲啶核心进一步设计并合成了另一类新型吲哚基-5-甲基菲啶衍生物,并评估了它们针对细菌细胞分裂蛋白 FtsZ 的抗菌活性。结果表明,吲哚基-5-甲基菲啶衍生物对各种耐药菌,包括耐甲氧西林金黄色葡萄球菌和万古霉素耐药肠球菌(VRE),具有显著改善的活性。其中,化合物 C5 对敏感(MIC=1μg/mL)、耐甲氧西林和临床分离的金黄色葡萄球菌具有优异的抗菌活性(MIC=2μg/mL)。C5 对小鼠红细胞的溶血活性较低,在初步药效学试验中表现出良好的体内抗菌效果。更重要的是,C5 难以诱导细菌耐药性。进一步的机制研究证明,C5 通过促进 FtsZ 聚合来抑制细菌的细胞分裂,导致聚合无序和结无序。因此,我们的研究结果表明,这类新型吲哚基-5-甲基菲啶衍生物具有成为未来抗菌药物的潜力。